Development of the BreastScan Ultrasound Diagnostic System
First written in FY2025-H1. 1 of 3 entries say "Restated". Latest entry: FY2026.
6 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「During the consolidated fiscal year, 株式会社マイクロソニック, a consolidated subsidiary, completed the regulatory approval and notification procedures for the Breast Scan ultrasound diagnostic device, which is intended for the early detection of breast disease, and proceeded with clinical evaluation at medical institutions in preparation for market launch. Research and development expenses for these activities totaled ¥64 million for the consolidated fiscal year.」
For the Breast Scan, regulatory approval and notification procedures as a medical device were completed, and the product advanced to the stage of clinical evaluation at medical institutions in preparation for its market launch. Research and development expenses amounted to ¥64 million. - FY2026-H1RestatedAnnual report
「In terms of profit, operating income was ¥216 million, down 58.6% year on year, ordinary income was ¥297 million, down 46.1%, and interim net income attributable to owners of the parent was ¥134 million, down 60.3%, owing to a decline in gross profit accompanying lower sales and an increase in selling, general and administrative expenses, including personnel expenses.」
The company continued to bear expenses during the interim consolidated accounting period on the assumption that research and development activities related to the Breast Scan ultrasound imaging device under development by マイクロソニック株式会社 would continue. - FY2025-H1First statedAnnual report
「Research and development expenses related to the Breast Scan ultrasound imaging device, currently under development by operating subsidiary マイクロソニック株式会社」
It was disclosed for the first time that マイクロソニック株式会社 is developing the Breast Scan ultrasound imaging device and recorded research and development expenses during the interim consolidated accounting period.